The correlation between asthma and allergic rhinitis—often referred to as "one airway, one disease"—makes Pranlukast a versatile tool for treating patients who suffer from both conditions simultaneously. By addressing the underlying leukotriene-mediated inflammation in both the upper and lower respiratory tracts, Pranlukast provides comprehensive relief from symptoms like nasal congestion, sneezing, and wheezing. This dual-action approach simplifies treatment regimens and reduces the need for multiple, disparate medications.

In the Pranlukast Market, the "Allergic Rhinitis" application is a significant revenue contributor. The increasing prevalence of seasonal and perennial allergies globally is driving the need for long-acting oral therapies that do not cause the drowsiness often associated with traditional antihistamines. Manufacturers are responding by developing combination therapies that pair Pranlukast with other anti-inflammatory agents, aiming to provide a synergistic effect that improves the overall quality of life for allergy sufferers.